ReviewChirurgie (Heidelberg, Germany)2026
[Esophageal NEN: update on diagnostics and surgical treatment].
Review in Chirurgie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine neoplasms (NEN) of the esophagus are rare biologically heterogeneous tumors predominantly with aggressive courses. The World Health Organization (WHO) classification 2019/2022 distinguishes between well-differentiated neuroendocrine tumors (NET), poorly differentiated neuroendocrine carcinomas (NEC) and mixed neuroendocrine/non-neuroendocrine neoplasms (MiNEN), a differentiation with direct therapeutic consequences. The vast majority of esophageal NENs are poorly differentiated NECs with a corresponding unfavorable prognosis. The diagnostics require an extended immunohistochemical panel, synaptophysin, CgA, INSM1, Ki-67, TTF‑1 and a complete investigation of predictive biomarkers, including PD-L1, dMMR/MSI and NGS, ideally even in the primary diagnostic facility. The functional imaging depends on the histological subtype:
Indexed as
Identifiers
42334584What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.